|
|
World Market for Cancer Vaccines 2007-2012Published by: Visiongain Published: Jan. 17, 2007 - 90 Pages Table of Contents1. Executive Summary 2. An Introduction to cancer Vaccines 2.1. Cancer incidence is on the increase 2.1.1. The most common cancers 2.1.2. Worldwide variation in cancer incidence and mortality 2.2. Cancer Biology 2.3. Infection, viruses and cancer 2.3.1. Human papilloma virus 2.3.2. Hepatitis viruses 2.3.3. Epstein-Barr virus 2.3.4. Human T-cell leukaemia virus 2.3.5. Helicobactor pylori 2.3.6. HIV 2.4. Prophylactic vaccines in the prevention of cancer 2.4.1. Types of prophylactic vaccines 2.5. The immune system and cancer 2.5.1. Tumour associated antigens 2.6. Therapeutic vaccines in the treatment of cancer 2.7. Types of therapeutic cancer vaccines, personalised versus generalised cancer vaccines 2.7.1. Whole-cell vaccines 2.7.2. Gene modified cancer vaccines 2.7.3. Dendritic cell cancer vaccines 2.7.4. Peptide cancer vaccines 2.7.5. Bacterial vector vaccines 2.7.6. Heat-shock protein vaccines 2.7.7. Viral vector vaccines 2.7.8. DNA vaccines 2.8. Could therapeutic vaccines provide a universal cure for cancer? 2.8.1. Cancer vaccines and telomerase 2.8.2. Cancer vaccines and metastasis 2.9. Summary 3. Demand analysis and forecasts of the world prophylactic cancer vaccines market 2006-2011 3.1. Key players in the prophylactic cancer vaccine market 3.1.1. GSK dominates the HBV vaccine market 3.1.2. Merck beat GSK in the race to launch the first cervical cancer vaccine 3.2 The world market for prophylactic cancer vaccines 3.3. The world market for hepatitis vaccines 3.3.1. The American market for hepatitis B vaccines 3.3.2. The European market for hepatitis B vaccines 3.3.3. The developing world market for hepatitis B vaccines 3.3.4. EngerixB is the biggest selling hepatitis B vaccine on the market 3.3.5. Other HBV vaccines on the market 3.3.6. Heplisav, predicted to be launched in 2009, will command a share of the market 3.4. Forecast of world sales of HBV vaccines 2007-2012 3.4.1. Engerix B will lose its hold on the market over the forecast period 3.4.2. The HBV market in 2012 3.5. The world market for HPV vaccines 3.5.1. The American market for HPV vaccines 3.5.2. The European market for HPV vaccines 3.5.3. Other markets for HPV vaccines 3.6. Forecast of world sales of HPV vaccines 2007-2012 3.6.1. Early sales of Gardasil are promising 3.6.2. Gardasil faces challenges from Cervarix and cultural barriers to obtain maximum potential sales of HPV vaccines 3.6.3. Gardasil will dominate the HPV market over the forecast period 2007-2012 3.7. HPV vaccines will emerge to dominate the prophylactic cancer vaccine market by 20012 3.8. Summary 4. The world market for therapeutic cancer vaccines 4.1. Key players in therapeutic cancer vaccines 4.1.1. AVAX Technologies and M-Vax 4.1.2. Intracel is seeking worldwide market approval for OncoVAX 4.1.3. Corixa and Melacine, a cautionary tale 4.1.4. Provenge could soon capitalise on the large prostate cancer market 4.1.5. TroVax is set to be the first allogeneic cancer vaccine to obtain a US license 4.1.6. The predicted therapeutic cancer vaccine market in 2012 4.2. The world market for cancer therapies 4.2.1. Biological therapies have made a mark on the cancer therapy market 4.3. Is there a place for cancer vaccines in the cancer therapy market? 4.3.1. The potential market for Provenge 4.3.2. The potential market for TroVax 4.3.3. The potential market for M-Vax 4.3.4. The potential market for OncoVax 4.4. Summary 5. Issues affecting the cancer vaccines market 5.1. Issues affecting the prophylactic cancer vaccine market 5.1.1. HPV and HBV vaccines will continue to make up the prophylactic cancer vaccine market 5.1.2. Public opinion and pricing may restrict the potential of prophylactic cancer vaccines 5.2. Issues affecting the therapeutic cancer vaccine market 5.2.1. Large potential markets for therapeutic cancer vaccines 5.2.2. Can therapeutic cancer vaccines prove their worth? 5.2.2. Can therapeutic cancer vaccines succeed- finding the right partner could be the key 5.2.3. Should you get involved in this emerging market? 5.3. Summary 6. The cancer vaccines pipeline 6.1. The prophylactic cancer vaccines pipeline 6.2. Overview of the therapeutic cancer vaccine pipeline 6.3. Autologous therapeutic cancer vaccines in phase III trials 6.4. Allogeneic therapeutic cancer vaccines in phase III trials 6.4.1. Could Pharmexa have the key to a generalised cancer vaccine? 6.4.1.1.Geron challenges Pharmexa's patents on telomerase vaccines 6.4.2. GVAX 6.4.3. PANVAC-VF 6.4.4. Alloverctin7 6.4.5. Stimuvax 6.5 Therapeutic cancer vaccines in phase II 6.5.1 Advaxis and live listeria vaccines 6.5.2. Trangene 6.6. Big companies get a foothold by buying into the market or forming alliances 6.6.1. GSK and The Ludgwig Institute for Cancer Research 6.6.2. Merck KGaA and SurvacApS 6.6.3 Merck & co buys into potential telomerase and DNA vaccine market 6.6.4. Sanofi-Aventis and Agensys, Inc. 6.7. The adjuvant market 6.6. Summary 7. Conclusion List of Tables Table 2.1. The most common cancers worldwide by cancer site Table 2.2 Rates of common cancers in developed and developing nations Table 2.3. Types of prophylactic cancer vaccines Table 2.4. Types of autolotgous and allogeneic cancer vaccines being developed Table 3.1. Prophylactic cancer vaccines currently on the market Table 3.2. World market for main HBV vaccines 2007-2012 Table 3.3. Sales forecast for main HBV vaccines 2007-2012 Table 3.4. World wide population of women aged 11-26 Table 3.5. The market for HPV vaccines 2007-2012 Table 3.6. Revenue forecasts for Gardasil and Cervarix 2007-2012 Table 4.1. Therapeutic cancer vaccines with licenses or predicted to obtain them within the forecast period Table 4.2. Top selling cancer therapies in 2005 Table 5.1. A SWOT chart for the prophylactic cancer vaccines market Table 5.2. A SWOT chart for the cancer vaccines market Table 6.1. Prophylactic cancer vaccines in development Table 6.2. Therapeutic cancer vaccines in phase III trials Table 6.3 Therapeutic cancer vaccines in phase II trials Table 6.4. Pharmexa's therapeutic cancer vaccines in development Table 6.5. Collaborations, licenses and acquisitions in therapeutic cancer vaccines List of Figures Figure 2.1. Incidence of and mortality of the most common cancers worldwide Figure 2.2. Incidence of and mortality from the most common male cancers Figure 2.3. Incidence of and mortality from the most common female cancers Figure 2.4. Rates of cancer incidence and mortality in developed nations Figure 2.5. Rates of cancer incidence and mortality in developing nations Figure 3.1. Company share of the prophylactic cancer vaccine market in 2005 Figure 3.2. The world market for hepatitis vaccines in 2005 Figure 3.3. 2005 market share of the main HBV vaccine market Figure 3.4. Sales forecast for EngerixB 2007-2012 Figure 3.5. Sales forecast for Twinrix 2007-2012 Figure 3.6. Sales forecast for Recombivax HB 2007-2012 Figure 3.7. Comparison of the sales forecast for main HBV vaccines 2007-2012 Figure 3.8. Comparison of growth rates of the main HBV vaccines Figure 3.9. The predicted market share of the main HBV vaccines in 2012 Figure 3.10. Estimated number of girls and women aged 11 and aged 11-26 Figure 3.11. Forecast for revenue of HPV vaccines 2007-2012 Figure 3.12. Market share of the HPV vaccine market 2007-2012 Figure 3.13. Predicted market share of the prophylactic cancer vaccines market in 2012 Figure 4.1. Predicted launch dates of cancer vaccines 2007-2012 Figure 4.2. Top selling cancer therapies in 2005 Figure 6.1. Types of cancer vaccines in development Figure 6.2. Cancers for which therapeutic vaccines are being developed Abstract"Lung cancer vaccine to be tested""New US bill requires cancer vaccine for girls" "Cancer vaccine too expensive" These are just some of the news headlines that have seen the world cancer vaccine market turned on its head. The benefits are unquestionable, the costs of the drugs however may yet see take-up slow. How will this effect your company? This report will tell you. There are two types of cancer vaccines:
Previously the cancer vaccine market has consisted of HBV (hepatitis B virus) vaccines to prevent liver cancer. 2006 saw the launch of Gardasil the first vaccine against HPV (human papilloma virus) to protect against cervical cancer. Another HPV vaccine, Cervarix, is due to be launched in 2007. These two vaccines are together predicted to generate sales of more than $4bn in 2012, which could see them becoming the top selling vaccines. Their success could lead a growth in the cancer vaccines market, resulting in it being worth 7 times what it is today. Will you be able to capture your share of the market place? Therapeutic cancer vaccines, designed to stimulate the immune system into killing existing cancers, also look likely to soon achieve commercial success, after much investment into their research and development. The first therapeutic cancer vaccine is expected to be launched in 2007, with a number of others predicted to obtain licenses in the next few years. Hw will this effect current cancer drugs and treatments? Understand today. The report gives an overview of the current and potential market for cancer vaccines, in particular concentrating on the following aspects of cancer vaccines:
Why you must by this report:
This report analyses the current situation in the market and assesses the potential of the products that are currently in the development pipeline. A comprehensive analysis of the addiction treatment market from 2006-2011 outlines the potential of the market. Visiongain expects to see the development of at least two multi-billion dollar markets. You and your company should be part of this market, and you could be by placing your order immediately. Unique benefits to you when you order this report:
Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. |
|
|||
|
About MarketResearch.com
|
||||